This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up
by Zacks Equity Research
Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.
Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioMarin (BMRN) is likely to provide an update on the sales of its key drugs Vimizim, Kuvan and others as well as how the pipeline has progressed when it reports Q2 earnings.
Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues decline year over year in first-quarter fiscal 2021.
Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker
by Zacks Equity Research
Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.
Mustang Bio (MBIO) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Mustang Bio (MBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
PhaseBio Initiates Phase II Study for Coronavirus Patients
by Zacks Equity Research
PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.
Dynavax Signs a Pact to Develop Universal Influenza Vaccine
by Zacks Equity Research
Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.
Tricida (TCDA) Plummets on Regulatory Update on Veverimer
by Zacks Equity Research
Tricida (TCDA) tanks on FDA notification about the identification of deficiencies in its ongoing review of the NDA for pipeline candidate, veverimer (TRC101).
Nabriva Soars on Agreement With Merck to Distribute Sivextro
by Zacks Equity Research
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
Trevena (TRVN) Looks Good: Stock Adds 8.8% in Session
by Zacks Equity Research
Trevena (TRVN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020
by Zacks Equity Research
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Blueprint Medicines, Roche to Develop Pralsetinib for Cancer
by Zacks Equity Research
Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.
Axsome's NDA for Depressive Disorder Drug on Track in Q420
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
by Zacks Equity Research
Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.
Celsion Down on DMC Recommendation to Stop Liver Cancer Study
by Zacks Equity Research
Celsion (CLSN) plummets on DMC recommendation to stop its phase III study assessing the efficacy of ThermoDox for HCC.
AbbVie (ABBV) Gets FDA Nod for Another Botox Label Expansion
by Zacks Equity Research
AbbVie (ABBV) wins the FDA nod for an expanded use of Botox to treat spasticity in pediatric patients aged two years and above including those with lower limb spasticity caused by cerebral palsy.
Abeona Restarts Enrollment in Connective Tissue Disorder Study
by Zacks Equity Research
Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.
CorMedix (CRMD) Jumps: Stock Rises 7.5%
by Zacks Equity Research
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Unum Therapeutics (UMRX) Catches Eye: Stock Jumps 8.6%
by Zacks Equity Research
Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
BioMarin's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in BioMarin Pharmaceutical.